Table 1.
List of parkin inducers identified by luciferase screening.
| Compounds | Luc | Indication | Note |
|---|---|---|---|
| Vorinostat (SAHA) | 3.4 | Cancer | HDAC inhibitor |
| Deferasirox (Exjade) | 2.9 | Endocrinology | Iron chelator |
| Sevelamer HCl | 2.6 | Cardiovascular Disease | Binds to dietary phosphate |
| Chloroquine Phosphate | 2.4 | Inflammation | Anti-malarial agent |
| Hydrocortisone (Cortisol) | 2.4 | Infection | Steroid hormone |
| Mycophenolic (Mycophenolate) | 2.3 | Infection | Immunosuppressant |
| Vinblastine | 2.2 | Neurological Disease | Inhibits microtubule formation |
| Diphenylpyraline HCl | 2.1 | Neurological Disease | |
| Penicillamine (Cuprimine) | 1.9 | Immunology | Antirheumatic agent |
| Sulindac (Clinoril) | 1.8 | Cancer | Non-steroidal anti-inflammatory drug |
| Isoetharine Mesylate | 1.7 | Cardiovascular Disease | |
| Atovaquone (Atavaquone) | 1.7 | Neurological Disease | Used to treat or prevent for pneumocystis pneumonia |
| ATP (Adenosine-Triphosphate) | 1.7 | Endocrinology | |
| Metformin hydrochloride (Glucophage) | 1.7 | Endocrinology | Biguanide hypoglycemic agent |
| Paromomycin Sulfate | 1.7 | Infection | Aminoglycoside antibioticis |
| Clindamycin | 1.7 | Infection | Inhibits protein synthesis by acting on the 50S ribosomal. |
| Isoniazid (Tubizid) | 1.7 | Infection | Angiogenesis |
| Azilsartan (TAK-536) | 1.7 | Neurological Disease | Angiotensin II type 1 (AT1) receptor antagonist |
| Fenoprofen calcium hydrate | 1.7 | Immunology | Non-steroidal anti-inflammatory drug |
| Meptazinol HCl | 1.6 | Neurological Disease | Opioid analgesic |
HEK-parkin-Luc reporter cells were treated with each compound. Parkin promoter activities were determined based on luciferase value (Luc.). They were normalized to that of DMSO control and expressed in the table (See also Fig. 1D). The clinical indication and note are adapted from the table provided by Selleck (L1300-Selleck-FDA-Approved-Drug-Library-1172cpd-Library).